The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy

The heparan sulfate proteoglycan syndecan-1 is expressed by myeloma cells and shed into the myeloma microenvironment. High levels of shed syndecan-1 in myeloma patient sera correlate with poor prognosis and studies in animal models indicate that shed syndecan-1 is a potent stimulator of myeloma tumo...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Yang, Yang, MacLeod, Veronica, Dai, Yuemeng, Khotskaya-Sample, Yekaterina, Shriver, Zachary, Venkataraman, Ganesh, Sasisekharan, Ram, Naggi, Annamaria, Torri, Giangiacomo, Casu, Benito, Vlodavsky, Israel, Suva, Larry J., Epstein, Joshua, Yaccoby, Shmuel, Shaughnessy, John D., Barlogie, Bart, Sanderson, Ralph D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2007
Gaiak:
Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC1976367/
https://ncbi.nlm.nih.gov/pubmed/17536013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-04-082495
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak